Alamar Biosciences, Inc. ALMR
Set alert
30.60 USD -3.44 -10.11%
At close · Oct 30
30.54 -0.06 -0.20%
After hours · Oct 30, 4:06 PM ET
29.36 Day range 33.85
19.09 52-week range 38.13
- YTD
- +39.09%
- 1 year
- +39.09%
- Open
- 33.35
- Prev close
- 34.04
- Mkt cap
- 2.12B
- Vol
- 740.07K
- Avg vol
- 537.55K
- EPS
- -1.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.36
- High
- 33.85
- Forward P/E
- -66.64
- Beta
- 0.00
- Short ratio
- 3.53
- Inst. own
- 57.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 30.73
- 200-d avg
- 26.90
- 1y target
- 35.40
MAX chart
Events in this range
- May 8, 2026Earnings: -1.74; estimate -1.71; surprise -1.75%
- May 12, 2026Rating: Stifel · — → Buy
- May 12, 2026Rating: JP Morgan · — → Overweight
- May 12, 2026Rating: TD Cowen · — → Buy
- May 12, 2026Rating: Leerink Partners · — → Outperform
- Aug 10, 2026Earnings: -0.22; estimate -0.30787; surprise 28.54%
- Aug 11, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 11, 2026Rating: Stifel · Buy → Buy
- Nov 3, 2026Earnings: —; estimate -0.2015; surprise —%
Signals (48)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 24, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 2.09B
- Enterprise value
- 2.16B
- Trailing P/E
- 0.00
- Forward P/E
- -66.64
- PEG ratio
- 0.00
- Price / sales
- 20.81
- Price / book
- 6.68
- EPS (TTM)
- -1.20
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -49.45%
- Revenue (TTM)
- 100.42M
- Revenue growth
- 82.10%
- Free cash flow
- 0
- Total cash
- 250.05M
- Total debt
- 51.41M
- Return on equity
- 0.00%
- Shares outstanding
- 69.39M
- Short % of float
- 6.25%
- 50-day average
- 30.73
- 200-day average
- 26.90
Analyst view
Consensus: none
Price target (mean) 35.40 +15.7% upside
Now 30.60
- Target (low)
- 31.00
- Target (mean)
- 35.40
- Target (high)
- 45.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.18688.
Financials — quick view
ALMR Revenue — quarterly 29.43M
ALMR Net income — quarterly -13.20M
ALMR EPS — quarterly -0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.2015 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.30787 | -0.22 | +0.09 | +28.54% |
| May 8, 2026 | Mar 31, 2026 | -1.71 | -1.74 | -0.03 | -1.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 2026 | Stifel | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| May 12, 2026 | Leerink Partners | init | — | Outperform |
| May 12, 2026 | TD Cowen | init | — | Buy |
| May 12, 2026 | JP Morgan | init | — | Overweight |
| May 12, 2026 | Stifel | init | — | Buy |
About Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- alamarbio.com
News
- Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
- Alamar: The Consumables Flywheel Is Just Getting Started
- Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
- Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
- Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday
- Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Alamar Biosciences: Promising But Expensive Proteomics Growth
- Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
Your note
Sign in to keep a note on ALMR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN SHIPING PH.D. | Chief Operating Officer | Stock Award(Grant) | Apr 19, 2026 | 760,105 |
| ILLUMINA INNOVATION FUND II GP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 19, 2026 | 0 |
| LUO YULING PH.D. | Chief Executive Officer | Stock Award(Grant) | Apr 19, 2026 | 3,164,730 |
| MCANEAR JUSTIN J | Chief Financial Officer | Stock Award(Grant) | Apr 19, 2026 | 37,220 |
| NACLERIO NICHOLAS J. | Director | Stock Award(Grant) | Apr 19, 2026 | 6,369,300 |
| QIMING CORPORATE GP VI, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 25, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 6.10% | 4,230,926 | 127.39M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 3.57% | 2,480,310 | 74.68M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.17% | 2,202,597 | 66.32M | Jun 29, 2026 |
| ARK Investment Management, LLC | 1.98% | 1,373,959 | 41.37M | Jun 29, 2026 |
| Braidwell LP | 1.56% | 1,083,983 | 32.64M | Jun 29, 2026 |
| Alliancebernstein L.P. | 1.45% | 1,003,077 | 30.20M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.42% | 984,456 | 29.64M | Sep 29, 2026 |
| ARK Venture Fund | 0.96% | 667,717 | 20.11M | Jul 30, 2026 |
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 0.87% | 601,045 | 18.10M | Aug 30, 2026 |
| Columbia Funds Series Trust I-Columbia Small Cap Growth Fund | 0.68% | 472,554 | 14.23M | Aug 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.51% | 355,864 | 10.72M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.50% | 345,070 | 10.39M | Sep 29, 2026 |